Giovanni Caforio, AP Images

Bris­tol My­ers Squibb takes an­oth­er late-stage loss for Op­di­vo-Yer­voy com­bo in head and neck can­cer

Bris­tol My­ers Squibb has worked over­time to hunt down an edge for its PD-(L)1 block­er Op­di­vo over ri­val Keytru­da from Mer­ck, in­clud­ing tak­ing a bold …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.